Walgreens Boots Alliance details new CEO search, shares digest recent earnings and guidance cut

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-26, 07:41.

Walgreens Boots Alliance, Inc. (US9314271019) is pushing ahead with its leadership transition and strategy reset after a sharp profit warning earlier in June. The company, whose shares trade on the NASDAQ, has launched a formal search for a permanent CEO while tightening its cost-saving program, according to recent management comments reported by U.S. business media.

What recent reports say

Walgreens Boots Alliance disclosed on 27 June 2024 that adjusted earnings per share for fiscal 2024 were now expected between 2.80 and 2.95 dollars, significantly below its previous outlook of 3.20 to 3.35 dollars, as U.S. retail and pharmacy margins came under pressure. In the same update the company cut its quarterly dividend from 48 cents to 25 cents per share, ending a long-standing pattern of dividend increases to fund strategic flexibility in the U.S. healthcare pivot.

On that earnings call, interim CEO Tim Wentworth emphasized that Walgreens would accelerate store closures, optimize labor scheduling and pursue additional procurement savings to protect profitability in a structurally more competitive U.S. pharmacy market that includes peers such as CVS Health and Walmart. Wentworth also confirmed that the board had initiated a structured process to identify a permanent chief executive, supported by external advisors, underscoring the importance of stable leadership as the group scales its VillageMD primary-care joint venture and specialty-pharmacy assets across the United States.

Analysts react to guidance cut

Following the June 2024 guidance cut and dividend reduction, several Wall Street houses adjusted their stance on Walgreens Boots Alliance, with some lowering price targets while others downgraded the shares to neutral or equivalent ratings. Market commentary in U.S. financial media highlighted that the downgrade wave reflected concerns about execution risk in U.S. healthcare services, reimbursement pressure in retail pharmacy and the balance-sheet impact of ongoing restructuring charges.

Analysts also noted that the company plans to close a further number of underperforming U.S. stores over the coming years, building on previous closure programs to focus on higher-volume locations and markets where health services such as vaccinations, diagnostics and chronic-disease management can be scaled more quickly. This strategic concentration, they argue, could support medium-term margins if executed consistently, but near-term earnings visibility remains muted as management navigates inflationary pressures in wages and logistics in a relatively low-growth U.S. consumer environment.

How Walgreens makes its money

Walgreens Boots Alliance generates the majority of its revenue from its U.S. Retail Pharmacy segment, which includes more than 8,000 Walgreens and Duane Reade stores across the United States offering prescription medications, over-the-counter drugs, beauty products and general retail items. The company also operates an International segment, historically centered around the Boots pharmacy chain in the United Kingdom, as well as a U.S. Healthcare segment that houses investments in VillageMD primary-care clinics, specialty pharmacy provider Shields Health Solutions and other health-service assets aimed at integrating care delivery with its pharmacy network.

Where the stock trades today

Walgreens Boots Alliance shares trade on the NASDAQ exchange in New York under the ticker WBA; recent quotes from major financial data providers show the stock changing hands in the mid-teens dollar range, reflecting the impact of the 2024 guidance cut and dividend reduction on investor sentiment.

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.